In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated
